Gilead Sciences Inc (LTS:0QYQ)
$ 89.755 0.23 (0.26%) Market Cap: 112.32 Bil Enterprise Value: 132.90 Bil PE Ratio: 109.56 PB Ratio: 6.12 GF Score: 75/100

Gilead Sciences Inc at Cowen Virtual Oncology Innovation Summit Transcript

May 21, 2021 / 04:00PM GMT
Release Date Price: $69.57 (+0.81%)
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good afternoon, and welcome once again to Cowen and Company's Second Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Gilead Sciences. We're really happy to have with us today, Merdad Parsey, the Chief Medical Officer of Gilead.

Merdad, thanks so much for joining us. I'm sure these are incredibly busy times for you.

Merdad V. Parsey
Gilead Sciences, Inc. - Chief Medical Officer

I really appreciate the invite, Phil. Good to see you. Thanks.

Questions & Answers

Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

I think we'll focus today's discussion specifically on your oncology pipeline in light of ASCO and EHA coming up. Maybe first, we'll start with Trodelvy. There's a vigorous debate on the Street about Trodelvy's TROPiCS-02 trial and ER-positive HER2

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot